Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03756688 · ClinicalTrials.gov registry record · NA
Penile Length Restoration in Men With Diabetes Mellitus, Type II
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 110
- Enrollment target
NCT03756688: Completed NA study, sponsored by Mayo Clinic.
NCT03756688 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 110 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03756688, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
Study Summary
The objective of the current study is to evaluate the efficacy of a novel penile traction device in restoring lost penile length in men with type 2 diabetes.
Primary Outcome
Primary objective of this study is to assess penile length pre and post completion of RestoreX traction therapy compared to control groups (no treatment) of Diabetes Type II patients. Measurements were obtained at baseline and 6 months post-prostatectomy.
Interventions
- DEVICE RestoreX PTT - 6 months
- DEVICE RestoreX PTT - 3 months
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2018-11-07 |
| Est. Completion | 2021-03-18 |
| Phase | NA |
What the finished NCT03756688 record still lists
NCT03756688 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which RestoreX PTT - 6 months is the first listed.
NCT03756688 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03756688 about?
NCT03756688 is a clinical study titled "Penile Length Restoration in Men With Diabetes Mellitus, Type II". The objective of the current study is to evaluate the efficacy of a novel penile traction device in restoring lost penile length in men with type 2 diabetes.
What is the current status of trial NCT03756688?
This trial is currently completed. It is a NA study. The enrollment target is 110 participants. The study started on 2018-11-07. Estimated completion is 2021-03-18.
What interventions are being tested in trial NCT03756688?
The interventions under investigation include: RestoreX PTT - 6 months (DEVICE), RestoreX PTT - 3 months (DEVICE).
Who is sponsoring clinical trial NCT03756688?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03756688's enrollment target sits among peer trials
110 816th of 2000 higher than 1,176 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI